Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Medical Virology"
DOI: 10.1002/jmv.24767
Abstract: There is little information on retreatment efficacy and predictors of the combination of ledipasvir and sofosbuvir (ledipasvir/sofosbuvir) for patients who fail to respond to NS5A inhibitors. NS5A resistance variants are known to persist for long… read more here.
Keywords: response; prior ns5a; treatment; hcv genotype ... See more keywords
The Discovery of Conformationally Constrained Bicyclic Peptidomimetics as Potent Hepatitis C NS5A Inhibitors
Sign Up to like & getrecommendations! Published in 2021 at "ACS Medicinal Chemistry Letters"
DOI: 10.1021/acsmedchemlett.1c00391
Abstract: HCV NS5A inhibitors are the backbone of directly acting antiviral treatments against the hepatitis C virus (HCV). While these therapies are generally highly curative, they are less effective in some specific HCV patient populations. In… read more here.
Keywords: conformationally constrained; discovery conformationally; hcv; chemistry ... See more keywords
Retreatment of patients with chronic hepatitis C, subtype 1b and cirrhosis, who failed previous direct‐acting antiviral therapy including first‐ and second‐generation NS5A inhibitors with ombitasvir/paritaprevir/ritonavir, dasabuvir + sofosbuvir + ribavirin
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Viral Hepatitis"
DOI: 10.1111/jvh.13254
Abstract: The use of direct‐acting antiviral agents (DAAs) in patients with chronic HCV genotype 1 infection results in sustained virologic response (SVR) rates of 95%‐97%, but 3%‐5% of patients experience virologic failure. We observed 17 patients… read more here.
Keywords: cirrhosis; generation; failed previous; patients chronic ... See more keywords
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens
Sign Up to like & getrecommendations! Published in 2017 at "PLoS ONE"
DOI: 10.1371/journal.pone.0177352
Abstract: Background Intracellular HCV-RNA reduction is a proposed mechanism of action of direct-acting antivirals (DAAs), alternative to hepatocytes elimination by pegylated-interferon plus ribavirin (PR). We modeled ALT and HCV-RNA kinetics in cirrhotic patients treated with currently-used… read more here.
Keywords: patients receiving; hcv rna; ns5a inhibitors; alt ... See more keywords
NS5A inhibitors unmask differences in functional replicase complex half-life between different hepatitis C virus strains
Sign Up to like & getrecommendations! Published in 2017 at "PLoS Pathogens"
DOI: 10.1371/journal.ppat.1006343
Abstract: Hepatitis C virus (HCV) RNA is synthesized by the replicase complex (RC), a macromolecular assembly composed of viral non-structural proteins and cellular co-factors. Inhibitors of the HCV NS5A protein block formation of new RCs but… read more here.
Keywords: hcv; half; ns5a inhibitors; hepatitis virus ... See more keywords
Design and Synthesis of Novel Bis-Imidazolyl Phenyl Butadiyne Derivatives as HCV NS5A Inhibitors
Sign Up to like & getrecommendations! Published in 2022 at "Pharmaceuticals"
DOI: 10.3390/ph15050632
Abstract: In today’s global plan to completely eradicate hepatitis C virus (HCV), the essential list of medications used for HCV treatment are direct-acting antivirals (DAAs), as interferon-sparing regimens have become the standard-of-care (SOC) treatment. HCV nonstructural… read more here.
Keywords: design synthesis; ns5a inhibitors; imidazolyl phenyl; bis imidazolyl ... See more keywords